


In the Claims

1(Original) A compound of the structural formula I:



5

Formula I

or a pharmaceutically acceptable salt, *in vivo* hydrolysable ester, enantiomer, diastereomer or mixture thereof: wherein,

10 R represents hydrogen, or C_{1-6} alkyl;

R^c and R^d independently represents hydrogen or halo;

R^e represents N or O;

15

X represents $-(CHR_7)_p$, $-(CHR_7)_pCO$;

Y represents $-CO(CH_2)_n$, CH_2 , or $-CH(OR)$;

20 Q represents N, or O, wherein R_2 is absent when Q is O;

R_w represents H, C_{1-6} alkyl, $-C(O)C_{1-6}$ alkyl, $-C(O)OC_{1-6}$ alkyl, $-SO_2N(R)_2$, $-SO_2C_{1-6}$ alkyl, $-SO_2C_{6-10}$ aryl, NO_2 , CN or $-C(O)N(R)_2$;

25 R_2 represents hydrogen, C_{1-10} alkyl, OH, C_{2-6} alkenyl, C_{1-6} alkylSR, $-(CH_2)_nO(CH_2)_mOR$, $-(CH_2)_nC_{1-6}$ alkoxy, $-(CH_2)_nC_{3-8}$ cycloalkyl, $-(CH_2)_nC_{3-10}$ heterocyclyl, $-N(R)_2$, $-COOR$, or $-(CH_2)_nC_{6-10}$ aryl, said alkyl, heterocyclyl, or aryl optionally substituted with 1-3 groups selected from R^a ;

- R₃ represents hydrogen, C₁₋₁₀ alkyl, -(CH₂)_nC₃₋₈ cycloalkyl, -(CH₂)_nC₃₋₁₀ heterocyclyl, -(CH₂)_nCOOR, -(CH₂)_nC₆₋₁₀ aryl, -(CH₂)_nNHR₈, -(CH₂)_nN(R)₂, -(CH₂)_nN(R₈)₂, -(CH₂)_nNHCOOR, -(CH₂)_nN(R₈)CO₂R, -(CH₂)_nN(R₈)COR, -
5 (CH₂)_nNHCOR, -(CH₂)_nCONH(R₈), aryl, -(CH₂)_nC₁₋₆ alkoxy, CF₃, -(CH₂)_nSO₂R, -(CH₂)_nSO₂N(R)₂, -(CH₂)_nCON(R)₂, -(CH₂)_nCONHC(R)₃, -(CH₂)_nCONHC(R)₂CO₂R, -(CH₂)_nCOR₈, nitro, cyano or halogen, said alkyl, alkoxy, heterocyclyl, or aryl optionally substituted with 1-3 groups of R^a;
- 10 or, R₂ and R₃ taken together with the intervening Q form a 3-10 membered carbocyclic or heterocyclic carbon ring optionally interrupted by 1-2 atoms of O, S, C(O) or NR, and optionally having 1-4 double bonds, and optionally substituted by 1-3 groups selected from R^a;
- 15 R₄ and R₅ independently represent hydrogen, C₁₋₆ alkoxy, OH, C₁₋₆ alkyl, COOR, SO₃H, -O(CH₂)_nN(R)₂, -O(CH₂)_nCO₂R, -OPO(OH)₂, CF₃, OCF₃, -N(R)₂, nitro, cyano, C₁₋₆ alkylamino, or halogen;



- represents C₆₋₁₀ aryl or C₃₋₁₀ heterocyclyl, said aryl or heterocyclyl
20 optionally substituted with 1-3 groups selected from R^a;

Z represents (CH₂)_nPO(OR)(OR*);

- R* represents hydrogen, or C₁₋₆ alkyl;

- 25 R₇ represents hydrogen, C₁₋₆ alkyl, -(CH₂)_nCOOR or -(CH₂)_nN(R)₂,

- R₈ represents -(CH₂)_nC₃₋₈ cycloalkyl, -(CH₂)_n 3-10 heterocyclyl, C₁₋₆ alkoxy or -(CH₂)_nC₅₋₁₀ heteroaryl, -(CH₂)_nC₆₋₁₀ aryl said heterocyclyl, aryl or heteroaryl
30 optionally substituted with 1-3 groups selected from R^a;

- R^a represents F, Cl, Br, I, CF₃, N(R)₂, NO₂, CN, -COR₈, -CONHR₈, -CON(R₈)₂, -O(CH₂)_nCOOR, -NH(CH₂)_nOR, -COOR, -OCF₃, -NHCOR, -SO₂R, -SO₂NR₂, -SR, (C₁-C₆ alkyl)O-, -(CH₂)_nO(CH₂)_mOR, -(CH₂)_nC₁₋₆ alkoxy, (aryl)O-, -(CH₂)_nOH, (C₁-C₆ alkyl)S(O)_m-, H₂N-C(NH)-, (C₁-C₆ alkyl)C(O)-, (C₁-C₆ alkyl)OC(O)NH-, -
35 (C₁-C₆ alkyl)NR_w(CH₂)_nC₃₋₁₀ heterocyclyl-R_w, -(C₁-C₆ alkyl)O(CH₂)_nC₃₋₁₀


heterocyclyl-R_w, -(C₁-C₆ alkyl)S(CH₂)_nC₃₋₁₀ heterocyclyl-R_w, -(C₁-C₆ alkyl)-C₃₋₁₀ heterocyclyl-R_w, -(CH₂)_n-Z¹-C(=Z²)N(R)₂, -(C₂₋₆ alkenyl)NR_w(CH₂)_nC₃₋₁₀ heterocyclyl-R_w, -(C₂₋₆ alkenyl)O(CH₂)_nC₃₋₁₀ heterocyclyl-R_w, -(C₂₋₆ alkenyl)S(CH₂)_nC₃₋₁₀ heterocyclyl-R_w, -(C₂₋₆ alkenyl)-C₃₋₁₀ heterocyclyl-R_w, -
 5 (C₂₋₆ alkenyl)-Z¹-C(=Z²)N(R)₂, -(CH₂)_nSO₂R, -(CH₂)_nSO₃H, -(CH₂)_nPO(OR)₂, C₃₋₁₀cycloalkyl, C₆₋₁₀ aryl, C₃₋₁₀ heterocyclyl, C₂₋₆ alkenyl, and C₁-C₁₀ alkyl, said alkyl, alkenyl, alkoxy, heterocyclyl and aryl optionally substituted with 1-3 groups selected from C₁-C₆ alkyl, CN, NO₂, OH, CON(R)₂ and COOR;

10 Z¹ and Z² independently represents NR_w, O, CH₂, or S;
 g is 0-1;
 m is 0-3;
 n is 0-3; and
 p is 0-3.


15 2(Original). The compound according claim 1 wherein p is 1-3, Y is -CO(CH₂)_n, Q is N, X is -(CHR₇)_p-, or -(CHR₇)_pCO-,.

20 3(Original). The compound according claim 1 wherein Q is O and R₂ is absent.

4(Original). The compound according to claim 2 wherein Z is PO(OR)(OR*), R₂ is C₁₋₁₀ alkyl or C₁₋₆ alkylOH, Y is -CO(CH₂)_n and R₃ is (CH₂)_nC₃₋₁₀ heterocyclyl, said heterocyclyl and alkyl optionally substituted with 1 to
 25 3 groups of R^a.






5(Original). The compound according to claim 4 wherein  is a 6 membered heteroaryl or phenyl optionally substituted with 1-3 groups selected from R^a.

30 6(Currently Amended). A compound according to claim 1 5

wherein  is pyridyl optionally substituted with 1-3 groups selected from R^a.

7(Original). A compound according to claim 1 which is in the form
 35 of a sodium or disodium salt.

8(Original). A compound which is:



or a pharmaceutically acceptable salt, in vivo hydrolysable ester, enantiomer, diastereomer or mixture thereof.

5 9(Currently Amended). A method Use of a compound of formula I in claim 1 for the manufacture of a medicament for the treatment of ocular hypertension or glaucoma comprising administering a compound of formula I accordingly to claim 1.

10 10(Currently Amended). A method Use of a compound of formula I in claim 1 for the manufacture of a medicament for the treatment of macular edema, macular degeneration, increasing retinal and optic nerve head blood velocity, increasing retinal and optic nerve oxygen tension, and/or a neuroprotective effect comprising administering a compound of formula I accordingly to claim 1.

15 11(Currently Amended). A method Use of a compound of formula I in claim 1 for the manufacture of a medicament for preventing repolarization or hyperpolarization of a mammalian cell containing potassium channel or for treating Alzheimer's Disease, depression, cognitive disorders, and/or arrhythmia disorders comprising administering a compound of formula I accordingly to claim 1.

20 12(Currently Amended). A method Use of a compound of formula I in claim 1 for the manufacture of a medicament for treating diabetes comprising administering a compound of formula I accordingly to claim 1.

25 13(Original). A composition comprising a compound of formula I of claim 1 and a pharmaceutically acceptable carrier.

30 14(Original). The composition according to Claim 13 wherein the compound of formula I is applied as a topical formulation, said topical formulation administered as a solution or suspension and optionally containing xanthan gum or gellan gum.

35 15(Currently Amended). A composition according to claim 14 wherein one or more of an active ingredient belonging to the group consisting of: β -adrenergic blocking agent, parasympatho-mimetic agent, sympathomimetic agent,

carbonic anhydrase inhibitor, EP4 agonist, a prostaglandin ~~or derivative thereof~~,
hypotensive lipid, neuroprotectant, and/or 5-HT2 receptor agonist is optionally added.

16(Original). A composition according to claim 15 wherein the β -
5 adrenergic blocking agent is timolol, betaxolol, levobetaxolol, carteolol, or
levobunolol; the parasympathomimetic agent is pilocarpine; the sympathomimetic
agent is epinephrine, brimonidine, iopidine, clonidine, or para-aminoclonidine, the
carbonic anhydrase inhibitor is dorzolamide, acetazolamide, metazolamide or
brinzolamide; the prostaglandin is latanoprost, travaprost, unoprostone, rescula, or
10 S1033, the hypotensive lipid is lumigan, the neuroprotectant is eliprodil, R-eliprodil or
memantine; and the 5-HT2 receptor agonist is 1-(2-aminopropyl)-3-methyl-1H-
imidazol-6-ol fumarate or 2-(3-chloro-6-methoxy-indazol-1-yl)-1-methyl-ethylamine.